Imbed Biosciences Partners with Spartan Medical® to Provide Advanced Surgical and Wound Care Products to U.S. Veterans and Military Members

Aug 24, 2021

FROM Business Wire 



August 24, 2021 12:41PM Eastern Daylight Time

Full Release

MADISON, Wis.–()–Imbed Biosciences, a developer of advanced biomaterials and soft tissue repair devices, announced today that it has signed a distribution agreement with Spartan Medical®. The distribution agreement will provide customers in the Department of Veterans Affairs (VA) and Department of Defense (DoD) access to both Microlyte® Matrix and Microlyte® Surgical product lines through Spartan Medical’s Distribution and Pricing Agreement (DAPA), and VA IDIQ Contract with the US federal government.

“The partnership with Spartan Medical® will accelerate the use of Microlyte® Surgical within VA Hospitals and DOD medical centers on procedures at risk for surgical site infection. We are proud to align with such a strong and highly-regarded partner”


The Veterans Health Administration (VHA) is the largest integrated health care system in the US, providing care at nearly 1,300 healthcare facilities to over 9 million Veterans enrolled in the VA health care program. Accessing this significant federal marketplace in partnership with Spartan Medical®, a Service-Disabled Veteran Owned Business (SDVOSB), marks an important commercial step forward for Imbed Biosciences.

“The partnership with Spartan Medical® will accelerate the use of Microlyte® Surgical within VA Hospitals and DOD medical centers on procedures at risk for surgical site infection. We are proud to align with such a strong and highly-regarded partner,” said Chris Lyon, Imbed’s Vice President of Sales.

Imbed Biosciences’ product portfolio consists of innovative advanced wound products for use across all wound types: chronic, surgical, traumatic, and burn wounds. In chronic wounds, healing is frequently subverted by the presence of bacteria and bioburden in the wound. Certain populations, like diabetics, have impaired circulation which results in difficulty clearing infections by the immune system. Microlyte® Matrix contains antimicrobial silver which helps reduce bioburden in the wound and has been correlated clinically with improved chronic wound healing. Notably, diabetes occurs at twice the rate in VA patients as it does in the general population in the US.

For surgical, traumatic, and burn wounds, microbial contamination is also a threat to healing. Across all specialties, surgical site infections (SSI) occur at a 2.6% rate. Infection rates are much higher in trauma and burn wounds. The typical SSI results in an additional 7-10 day hospital stay and a cost of treatment as high as $30,000, representing a significant cost to the US government at the nation’s 171 VA Medical Centers and 50 DOD hospitals and inpatient facilities. To help combat SSI, Microlyte® Surgical also contains bacteria-killing antimicrobial silver, and reduction of bacterial bioburden in surgical and burn wounds may reduce microbial colonization and risks of infection in those wounds.

“The expansion of Microlyte® Surgical distribution with a partner like Spartan Medical® will further enable the important work that Imbed is doing to reduce the incidence and associated costs of surgical site infections in the US. We are particularly grateful for the opportunity to serve America’s wounded warriors and veterans through this partnership,” said Ankit Agarwal, Imbed Biosciences’ President and CEO.

“Spartan Medical® is honored to join forces with market innovators like Imbed Biosciences, focused on bringing game-changing technologies that reduce costs, while improving efficiencies and patient care, to our fellow veterans and wounded warriors. Ensuring we can bring the very best, to those who have served, is simply part of our Spartan DNA,” said Vince Proffitt, Spartan Medical’s President and CEO.

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and soft-tissue repair. The company has a portfolio of products in development based on its patented Microlyte® Matrix polymeric multilayer platform that presents bioactive molecules on tissue surfaces to combat local pain and infections, support soft-tissue repair, and reduce antibiotic over prescription and opioid abuse. Imbed is backed by private venture capital and has received research grants from the National Institutes of Health and the National Science Foundation. For more information, please visit,

About Spartan Medical®

Spartan Medical Inc. was founded in 2008 by a former Air Force Intelligence Officer to provide an extensive portfolio of advanced medical devices and technologies from premier partners, focused on the needs of the VA and DoD surgeon. Spartan Medical® is considered a top priority vendor in the VA as a CVE certified Service-Disabled Veteran-Owned Small Business (SDVOSB), and has been awarded 600+ Federal Government contracts including multi-year Blanket Purchase Agreements at over 30 major military treatment facilities with 13+ years of flawless performance.


Imbed Biosciences
Jeff Dalsin, 608-237-1524